253 related articles for article (PubMed ID: 30225651)
1. Low-Grade Serous Ovarian Cancer: Current Treatment Paradigms and Future Directions.
Grisham RN; Iyer G
Curr Treat Options Oncol; 2018 Sep; 19(11):54. PubMed ID: 30225651
[TBL] [Abstract][Full Text] [Related]
2. Low-grade Serous Tumors: Are We Making Progress?
Pauly N; Ehmann S; Ricciardi E; Ataseven B; Bommert M; Heitz F; Prader S; Schneider S; du Bois A; Harter P; Baert T
Curr Oncol Rep; 2020 Jan; 22(1):8. PubMed ID: 31989304
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic opportunities for women with low-grade serous ovarian cancer.
Moujaber T; Balleine RL; Gao B; Madsen I; Harnett PR; DeFazio A
Endocr Relat Cancer; 2021 Nov; 29(1):R1-R16. PubMed ID: 34636747
[TBL] [Abstract][Full Text] [Related]
4. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
5. Advancements in Low-Grade Serous Carcinoma of the Ovary and Peritoneum.
Grisham RN; Chui MH
Curr Oncol Rep; 2022 Nov; 24(11):1549-1555. PubMed ID: 35962920
[TBL] [Abstract][Full Text] [Related]
6. Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.
McLachlan J; Gore M; Banerjee S
Pharmacogenomics; 2016 Aug; 17(12):1353-63. PubMed ID: 27469379
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review.
Lazurko C; Linder R; Pulman K; Lennox G; Feigenberg T; Fazelzad R; May T; Zigras T
Curr Oncol; 2023 Sep; 30(9):8159-8171. PubMed ID: 37754507
[TBL] [Abstract][Full Text] [Related]
8. Novel therapeutics in low-grade serous ovarian cancer.
Cobb L; Gershenson D
Int J Gynecol Cancer; 2023 Mar; 33(3):377-384. PubMed ID: 36878564
[TBL] [Abstract][Full Text] [Related]
9. Hormone maintenance therapy for women with low-grade serous ovarian cancer in the front-line setting: A systematic review.
Lazurko C; Clark M; Pulman K; Lennox G; May T; Fazelzad R; Gien LT; Zigras T
Gynecol Oncol; 2021 Oct; 163(1):209-214. PubMed ID: 34325937
[TBL] [Abstract][Full Text] [Related]
10. Advances in precision therapy of low-grade serous ovarian cancer: A review.
Wang Q; Cao SH; Li YY; Zhang JB; Yang XH; Zhang B
Medicine (Baltimore); 2024 Apr; 103(17):e34306. PubMed ID: 38669365
[TBL] [Abstract][Full Text] [Related]
11. The highs and lows of serous ovarian cancer.
Grisham RN; Manning-Geist BL; Chui MH
Cancer; 2023 Sep; 129(17):2613-2620. PubMed ID: 37366225
[TBL] [Abstract][Full Text] [Related]
12. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
[TBL] [Abstract][Full Text] [Related]
13. Low-grade epithelial ovarian cancer: a number of distinct clinical entities?
Oswald AJ; Gourley C
Curr Opin Oncol; 2015 Sep; 27(5):412-9. PubMed ID: 26241347
[TBL] [Abstract][Full Text] [Related]
14. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
15. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V
Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
Manning-Geist BL; Kahn RM; Nemirovsky D; Girshman J; Laibangyang A; Gordhandas S; Iasonos A; Chui MH; Long Roche K; Zivanovic O; Chi DS; Aghajanian C; Grisham RN
Cancer; 2023 Jul; 129(13):2004-2012. PubMed ID: 36951509
[TBL] [Abstract][Full Text] [Related]
17. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
18. Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
Grisham RN; Sylvester BE; Won H; McDermott G; DeLair D; Ramirez R; Yao Z; Shen R; Dao F; Bogomolniy F; Makker V; Sala E; Soumerai TE; Hyman DM; Socci ND; Viale A; Gershenson DM; Farley J; Levine DA; Rosen N; Berger MF; Spriggs DR; Aghajanian CA; Solit DB; Iyer G
J Clin Oncol; 2015 Dec; 33(34):4099-105. PubMed ID: 26324360
[TBL] [Abstract][Full Text] [Related]
19. Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability.
Shrestha R; Llaurado Fernandez M; Dawson A; Hoenisch J; Volik S; Lin YY; Anderson S; Kim H; Haegert AM; Colborne S; Wong NKY; McConeghy B; Bell RH; Brahmbhatt S; Lee CH; DiMattia GE; Le Bihan S; Morin GB; Collins CC; Carey MS
Cancer Res; 2021 Apr; 81(7):1681-1694. PubMed ID: 33441310
[TBL] [Abstract][Full Text] [Related]
20. Upfront HIPEC and bevacizumab-containing adjuvant chemotherapy in advanced epithelial ovarian cancer.
Paris I; Cianci S; Vizzielli G; Fagotti A; Ferrandina G; Gueli Alletti S; Costantini B; Cosentino F; Capoluongo E; Pasqualoni M; Scambia G
Int J Hyperthermia; 2018; 35(1):370-374. PubMed ID: 30300042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]